A detailed history of Independence Bank Of Kentucky transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Independence Bank Of Kentucky holds 400 shares of GILD stock, worth $36,540. This represents 0.01% of its overall portfolio holdings.

Number of Shares
400
Previous 525 23.81%
Holding current value
$36,540
Previous $36,000 8.33%
% of portfolio
0.01%
Previous 0.01%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 09, 2024

SELL
$66.59 - $83.99 $8,323 - $10,498
-125 Reduced 23.81%
400 $33,000
Q1 2024

Apr 16, 2024

SELL
$71.58 - $87.29 $5,368 - $6,546
-75 Reduced 12.5%
525 $38,000
Q1 2023

Apr 06, 2023

SELL
$77.31 - $88.08 $4,793 - $5,460
-62 Reduced 9.37%
600 $49,000
Q4 2022

Jan 09, 2023

BUY
$62.32 - $89.47 $11,653 - $16,730
187 Added 39.37%
662 $57,000
Q3 2022

Oct 06, 2022

SELL
$59.54 - $68.01 $23,875 - $27,272
-401 Reduced 45.78%
475 $29,000
Q1 2022

Apr 14, 2022

BUY
$57.92 - $72.58 $23,225 - $29,104
401 Added 84.42%
876 $52,000
Q3 2021

Oct 26, 2021

SELL
$67.69 - $73.03 $13,538 - $14,606
-200 Reduced 29.63%
475 $33,000
Q2 2021

Jul 23, 2021

SELL
$63.47 - $69.35 $1,586 - $1,733
-25 Reduced 3.57%
675 $46,000
Q4 2020

Jan 22, 2021

SELL
$56.65 - $64.55 $5,834 - $6,648
-103 Reduced 12.83%
700 $41,000
Q3 2020

Oct 05, 2020

BUY
$62.1 - $78.08 $4,533 - $5,699
73 Added 10.0%
803 $51,000
Q2 2019

Jul 23, 2019

SELL
$61.87 - $69.38 $6,187 - $6,938
-100 Reduced 12.05%
730 $49,000
Q4 2018

Jan 28, 2019

SELL
$60.54 - $79.0 $11,502 - $15,010
-190 Reduced 18.63%
830 $52,000
Q3 2018

Oct 17, 2018

BUY
$71.28 - $78.92 $2,138 - $2,367
30 Added 3.03%
1,020 $79,000
Q4 2017

Feb 08, 2018

BUY
$71.15 - $83.52 $70,438 - $82,684
990
990 $71,000

Others Institutions Holding GILD

About GILEAD SCIENCES, INC.


  • Ticker GILD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,253,369,984
  • Market Cap $114B
  • Description
  • Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...
More about GILD
Track This Portfolio

Track Independence Bank Of Kentucky Portfolio

Follow Independence Bank Of Kentucky and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Independence Bank Of Kentucky, based on Form 13F filings with the SEC.

News

Stay updated on Independence Bank Of Kentucky with notifications on news.